Heart patients who suffer Takotsubo cardiomyopathy (TC) could face longer hospital stays, poorer outcomes and more than $150,000 in hospital bills if they’re undergoing chemotherapy simultaneously, researchers report in the American Journal of Cardiology.

Data presented at the 2018 EuroEcho-Imaging congress in Milan suggest breast cancer patients who take the common chemo drug trastuzumab might be able to mitigate their risk of heart damage by supplementing with carvedilol, a beta-blocker used predominantly by cardiac patients.

Home telemonitoring approaches for heart failure patients are associated with lower odds of death at six months but not beyond that, according to a meta-analysis published in the December issue of Health Affairs.

Seniors taking five or more prescription drugs to treat heart failure could be at an increased risk for functional impairment, according to a study published in the Journal of the American Geriatrics Society.

Using a biomarker target to guide the treatment of patients with heart failure with reduced ejection fraction (HFrEF) resulted in higher healthcare costs without significant improvements in quality of life compared to standard treatment, according to an analysis from the GUIDE-IT study.

Results from a study published in the Journal of Women’s Health Nov. 27 suggest both miscarriages and a high number of births have a significant impact on women’s cardiovascular health, raising a mother’s risk for coronary heart disease (CHD), heart failure and even serious MI.

Scientists at the University of Oxford are pitching cardiologists a new model for heart regeneration research: the Mexican tetra fish, a blind, translucent animal with an innate ability to repair its damaged heart tissue.

The idea of “rapid and complete recovery” in Takotsubo patients is a myth, according to research published in the Nov. 7 edition of the European Heart Journal—and it’s one physicians should be paying more attention to.